90 results found.

Sarcoma Clinical Trial using Specimen protocol

Memorial Sloan-Kettering Cancer Center - Recruiting N/A or older.
- Novel Biochemical and Molecular Determinants for Soft Tissue Sarcoma.
Specimen protocol

Neutropenia Clinical Trial using HM10460A (45 æg/kg); HM10460A (135 æg/kg); HM10460A (270 æg/kg); Pegfilgrastim 6mg

Spectrum Pharmaceuticals, Inc - Recruiting 18 years or older.
- Phase 2, Open-Label, Dose-Ranging Study of HM10460A or Pegfilgrastim Use for the Management of Neutropenia in Patients With Breast Cancer Who Are Candidates for Adjuvant and Neoadjuvant Chemotherapy With the Docetaxel + Cyclophosphamide (TC) Regimen.
HM10460A (45 æg/kg); HM10460A (135 æg/kg); HM10460A (270 æg/kg); Pegfilgrastim 6mg

Kaposi's Sarcoma, HIV+, HIV Positive, or AIDS Clinical Trial using aldoxorubicin

CytRx - Recruiting 18 years or older.
- An Open-Label Pilot Phase 2 Study to Investigate Efficacy, Safety, and Intratumoral Kinetics of ALDOXORUBICIN in HIV-Infected Patients With Kaposi's Sarcoma.
aldoxorubicin

Advanced Soft Tissue Sarcoma Clinical Trial using TRC105 and Pazopanib

Tracon Pharmaceuticals Inc. - Recruiting 18 years or older.
- A Phase 1B Dose-escalation Study of TRC105 in Combination With Pazopanib in Patients With Advanced Soft Tissue Sarcoma.
TRC105 and Pazopanib

Osteosarcoma Clinical Trial using Tissue Procurement

Memorial Sloan-Kettering Cancer Center - Recruiting N/A or older.
- Chemotherapy Resistance in Osteogenic Sarcoma and Other Solid Tumors.
Tissue Procurement

Ovarian Carcinosarcoma, Recurrent Ovarian Epithelial Cancer, Recu Clinical Trial using paclitaxel; carboplatin; ifosfamide

Gynecologic Oncology Group - Recruiting 18 years or older.
- A Randomized Phase III Trial of Paclitaxel Plus Carboplatin Versus Ifosfamide Plus Paclitaxel in Chemotherapy-Naive Patients With Newly Diagnosed Stage I-IV, Persistent or Recurrent Carcinosarcoma (Mixed Mesodermal Tumors) of the Uterus, Fallopian Tube, Peritoneum or Ovary.
paclitaxel; carboplatin; ifosfamide

Glioblastoma Clinical Trial using aldoxorubicin

CytRx - Recruiting 18 years or older.
- An Open-Label Pilot Phase 2 Study to Investigate the Preliminary Efficacy and Safety of Aldoxorubicin in Subjects With Unresectable Glioblastoma Whose Tumors Have Progressed Following Prior Treatment With Surgery, Radiation and Temozolomide.
aldoxorubicin

Locally Advanced or Metastatic Non Small Cell Lung Cancer Stage I Clinical Trial using Selumetinib; Docetaxel; Placebo; Pegylated G-CSF

AstraZeneca - Recruiting 18 years or older.
- A Phase III, Double-Blind, Randomised, Placebo-Controlled Study to Assess the Efficacy and Safety of Selumetinib (AZD6244; ARRY-142886) (Hyd-Sulfate) in Combination With Docetaxel, in Patients Receiving Second Line Treatment for KRAS Mutation-Positive Locally Advanced or Metastatic Non Small Cell Lung Cancer (Stage IIIB - IV) (SELECT 1).
Selumetinib; Docetaxel; Placebo; Pegylated G-CSF

Sarcoma Clinical Trial using Ra-223 Dichloride

M.D. Anderson Cancer Center - Recruiting 15 years or older.
- Phase I Dose Escalation of Monthly Intravenous Ra-223 Dichloride in Osteosarcoma.
Ra-223 Dichloride

Leukemia, Lymphoma, Neuroblastoma, Sarcoma, or Desmoplastic Small Clinical Trial using Melphalan; Fludarabine; Cyclophosphamide; Cytarabine; Prednisone; Vincristine; Doxorubicin; Etoposide; Filgrastim; NK-DLI Infusions

National Institutes of Health Clinical Center (CC) - Recruiting 4 years to 35 years.
- A Phase I Study of NK Cell Infusion Following Allogeneic Peripheral Blood Stem Cell Transplantation From Related or Matched Unrelated Donors in Pediatric Patients With Solid Tumors and Leukemias.
Melphalan; Fludarabine; Cyclophosphamide; Cytarabine; Prednisone; Vincristine; Doxorubicin; Etoposide; Filgrastim; NK-DLI Infusions

Solid Tumors, Brain Tumors, Sarcoma, Wilm's Tumor, or Rhabdomyosa Clinical Trial using NK cellular therapy; rhIL-15

National Institutes of Health Clinical Center (CC) - Recruiting 2 years to 29 years.
- A Phase I Study of Autologous Activated Natural Killer (NK) Cells +/- rhIL15 in Children and Young Adults With Refractory Solid Tumors.
NK cellular therapy; rhIL-15

Ewing's Sarcoma, Leukemia, Lymphoma, Neoplasm, or Sarcoma Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting 3 Months to 40 years.
- Treatment of Children With Cancer.

HIV Infection, or Kaposi's Sarcoma Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- Collection of Blood, Bone Marrow, Tumor, or Tissue Samples From Patients With HIV Infection, KSHV Infection, Viral-Related Pre-Malignant Lesions, and/or Cancer.

Pediatric Cancer, Leukemia, Sarcoma, or Brain Tumors Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting N/A to 18 years.
- Protocol for the Enrollment on the Official COG Registry, The Childhood Cancer Research Network (CCRN) Children s Oncology Group.

Ewing's Sarcoma/Soft Tissue Sarcoma, Neuroblastoma, or Brain Tumo Clinical Trial using plerixafor

Sanofi - Recruiting 1 year to 18 years.
- A Phase 1/2 Combined Dose Ranging and Randomized, Open-label, Comparative Study of the Efficacy and Safety of Plerixafor in Addition to Standard Regimens for Mobilization of Haematopoietic Stem Cells Into Peripheral Blood, and Subsequent Collection by Apheresis, Versus Standard Mobilization Regimens Alone in Pediatric Patients, Aged 1 to <18 Years, With Solid Tumours Eligible for Autologous Transplants..
plerixafor

Bone Cancer, Chondrosarcoma, Ewing's Sarcoma, Osteosarcoma, or Rh Clinical Trial using Feraheme; MR Scan

Stanford University - Recruiting 8 years to 30 years.
- Pilot Differentiation of Bone Sarcomas and Osteomyelitis With Ferumoxytol-Enhanced MRI.
Feraheme; MR Scan

Sarcoma, Stomach Neoplasms, or Neoplasms Clinical Trial using Pazopanib; ARQ 197

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- Phase Ib Study of the Combination of Pazopanib, an Oral VEGFR Inhibitor, and ARQ 197 (Tivantinib), an Oral MET Inhibitor, in Patients With Refractory Advanced Solid Tumors.
Pazopanib; ARQ 197

Sarcoma, Endocrine Tumors, Neuroblastoma, Retinoblastoma, or Rena Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting N/A or older.
- Comprehensive Omics Analysis of Pediatric Solid Tumors and Establishment of a Repository for Related Biological Studies.

Neuroblastoma;, Rhabdomyosarcoma;, Ewing's Sarcoma;, Ewing's Tumo Clinical Trial using nab-paclitaxel

Celgene Corporation - Recruiting 6 Months to 21 years.
- A Phase 1 / 2, Multicenter, Open-label, Dose-finding Study to Assess the Safety, Tolerability, and Preliminary Efficacy of Weekly Nab-paclitaxel in Pediatric Patients With Recurrent or Refractory Solid Tumors.
nab-paclitaxel

Metastatic Cancers Other Than Melanoma That Express ESO Antigen, Clinical Trial using Anti-NY ESO-1 mTCR PBL; Aldesleukin; Cyclophosphamide; Fludarabine

National Institutes of Health Clinical Center (CC) - Recruiting 18 years to 66 years.
- Phase II Study of Metastatic Cancer That Expresses NY-ESO-1 Using Lymphodepleting Conditioning Followed by Infusion of Anti-NY ESO-1 Murine TCR-Gene Engineered Lymphocytes.
Anti-NY ESO-1 mTCR PBL; Aldesleukin; Cyclophosphamide; Fludarabine

Askin Tumor, Localized Ewing Sarcoma/Peripheral Primitive Neuroec Clinical Trial using laboratory biomarker analysis

Children's Oncology Group - Recruiting N/A to 21 years.
- A COG Study for Collecting and Banking Ewing Sarcoma Specimens.
laboratory biomarker analysis

Ewing Sarcoma, Gastrointestinal Tumor, Germ Cell Tumor, Hepatic T Clinical Trial using alemtuzumab; fludarabine; sirolimus; Busulfan; melphalan; stem cells

St. Jude Children's Research Hospital - Recruiting 2 years to 21 years.
- A Phase I Study of CD45RA+ Depleted Haploidentical Stem Cell Transplantation in Children With Relapsed or Refractory Solid Tumors and Lymphomas.
alemtuzumab; fludarabine; sirolimus; Busulfan; melphalan; stem cells

Metastatic and Locally Advanced Soft Tissue Tumor Patients Unfit Clinical Trial using Trabectedin

Italian Sarcoma Group - Recruiting 18 years to 80 years.
- SAFETY AND ACTIVITY OF TRABECTEDIN AS FIRST LINE IN ADVANCED SOFT TISSUE SARCOMA (STS) PATIENTS UNFIT TO RECEIVE STANDARD CHEMOTHERAPY: A PROSPECTIVE PHASE II STUDY WITH CLINICAL AND MOLECULAR CORRELATES.
Trabectedin

Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor (PNET) Clinical Trial using laboratory biomarker analysis; questionnaire administration

Children's Oncology Group - Recruiting N/A or older.
- Genetic Epidemiology of Ewing's Sarcoma.
laboratory biomarker analysis; questionnaire administration

Sarcoma Clinical Trial using Regorafenib; Placebo

Centre Oscar Lambret - Recruiting 18 years or older.
- Activity and Safety of Regorafenib in Patients With Metastatic Soft Tissue Sarcoma Previously Treated With Anthracycline-based Chemotherapy : a Multinational, Randomized, Phase II, Placebo-controlled Trial.
Regorafenib; Placebo

Sarcoma Clinical Trial using Trabectedin

Janssen Research & Development, LLC - Recruiting 15 years or older.
- A Multicenter, Open-Label Single-Arm Study of YONDELIS (Trabectedin) for Subjects With Locally Advanced or Metastatic Soft Tissue Sarcoma Excluding Leiomyosarcoma and Liposarcoma Who Have Relapsed or Are Refractory to Standard of Care Treatment.
Trabectedin

Sarcoma Clinical Trial using therapeutic conventional surgery; 3-dimensional conformal radiation therapy

European Organisation for Research and Treatment of Cancer - EORTC - Recruiting 18 years or older.
- A Phase III Randomized Study of Preoperative Radiotherapy Plus Surgery Versus Surgery Alone for Patients With Retroperitoneal Sarcoma (RPS).
therapeutic conventional surgery; 3-dimensional conformal radiation therapy

Ewing's Sarcoma Clinical Trial using Standard treatment (as per protocol ISG SSG III); Intensified chemotherapy

Italian Sarcoma Group - Recruiting N/A to 40 years.
- Phase III Study on Efficacy of Dose Intensification in Patients With Non-metastatic Ewing Sarcoma..
Standard treatment (as per protocol ISG SSG III); Intensified chemotherapy

Adult Rhabdomyosarcoma, Childhood Desmoplastic Small Round Cell T Clinical Trial using biologic sample preservation procedure; laboratory biomarker analysis

Children's Oncology Group - Recruiting N/A to 50 years.
- A COG Soft Tissue Sarcoma Diagnosis, Biology and Banking Protocol.
biologic sample preservation procedure; laboratory biomarker analysis

Ewing Sarcoma, or Sarcoma Clinical Trial using Mithramycin

National Institutes of Health Clinical Center (CC) - Recruiting 1 year or older.
- Phase I/II Trial of Mithramycin in Children and Adults With Refractory Extracranial Solid Tumors (Phase I) or Ewing Sarcoma and EWSFLI1 Fusion Transcript (Phase II).
Mithramycin

Sarcoma, Solid Tumors, Pulmonary Metastases, Lung Metastases, Ost Clinical Trial using Aerosol IL-2; Symptom Assessment

M.D. Anderson Cancer Center - Recruiting 12 years or older.
- Phase I/II Study of Aerosol Interleukin-2 for Pulmonary Metastases.
Aerosol IL-2; Symptom Assessment

Adult Supratentorial Primitive Neuroectodermal Tumor (PNET), Ewin Clinical Trial using etoposide; ifosfamide; intensity-modulated radiation therapy; topotecan hydrochloride; busulfan; melphalan; autologous hematopoietic stem cell transplantation; peripheral blood stem cell transplantation; autologous bone marrow transplantation

City of Hope Medical Center - Recruiting 6 Months to 40 years.
- A Pilot Study of Whole-body MRI-guided Intensity Modulated Radiation Therapy Combined With Systemic Chemotherapy Followed by High-Dose Chemotherapy With Busulfan, Melphalan and Topotecan and Stem Cell Rescue in Patients With Poor Risk Ewing's Sarcoma.
etoposide; ifosfamide; intensity-modulated radiation therapy; topotecan hydrochloride; busulfan; melphalan; autologous hematopoietic stem cell transplantation; peripheral blood stem cell transplantation; autologous bone marrow transplantation

Sarcoma, Synovial Clinical Trial using OTSA101-DTPA-90Y level 1; OTSA101-DTPA-90Y level 2; OTSA101-DTPA-90Y level 3

Centre Leon Berard - Recruiting 18 years or older.
- First in Man Study Investigating the Biodistribution, the Safety and Optimal Recommended Dose of a New Radiolabelled Monoclonal Antibody Targeting Frizzled Homolog 10 (FZD10) in Patients With Relapsed or Refractory Non Resectable Synovial Sarcomas.
OTSA101-DTPA-90Y level 1; OTSA101-DTPA-90Y level 2; OTSA101-DTPA-90Y level 3

Adult Alveolar Soft-part Sarcoma, Adult Angiosarcoma, Adult Desmo Clinical Trial using vismodegib; gamma-secretase/Notch signalling pathway inhibitor RO4929097; laboratory biomarker analysis; pharmacological study

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Phase 1B/II Study of GDC-0449 (NSC 747691) in Combination With RO4929097, a Gamma-Secretase Inhibitor (GSI) in Advanced/Metastatic Sarcomas.
vismodegib; gamma-secretase/Notch signalling pathway inhibitor RO4929097; laboratory biomarker analysis; pharmacological study

Hemangiosarcoma, or Soft Tissue Sarcoma Clinical Trial using Paclitaxel in combination with Bevacizumab

Stanford University - Recruiting 13 years or older.
- Paclitaxel in Combination With Bevacizumab (Avastinr) for the Treatment of Metastatic or Unresectable Angiosarcoma.
Paclitaxel in combination with Bevacizumab

Adult Supratentorial Primitive Neuroectodermal Tumor (PNET), Chil Clinical Trial using vincristine sulfate; doxorubicin hydrochloride; cyclophosphamide; ifosfamide; etoposide; topotecan hydrochloride; laboratory biomarker analysis

Children's Oncology Group - Recruiting N/A to 50 years.
- A Phase III Randomized Trial of Adding Vincristine-Topotecan-Cyclophosphamide to Standard Chemotherapy in Initial Treatment of Non-Metastatic Ewing Sarcoma.
vincristine sulfate; doxorubicin hydrochloride; cyclophosphamide; ifosfamide; etoposide; topotecan hydrochloride; laboratory biomarker analysis

Lung Cancer, Esophageal Cancer, Malignant Pleural Mesothelioma, S Clinical Trial using H1299 Lysate Vaccine; Cyclophosphamide; Celecoxib

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- Adjuvant Tumor Lysate Vaccine and Iscomatrix With or Without Metronomic Oral Cyclophosphamide and Celecoxib in Patients With Malignancies Involving Lungs, Esophagus, Pleura, or Mediastinum.
H1299 Lysate Vaccine; Cyclophosphamide; Celecoxib

Adult Soft Tissue Sarcoma Clinical Trial using NBTXR3

Nanobiotix - Recruiting 18 years or older.
- An Open-Label, Single Arm, Feasibility And Safety Phase I Study With Nbtxr3 Intratumor Implantation (By Injection) And Activated By External Beam Radiation Therapy In Patients With Soft Tissue Sarcoma Of The Extremity And Trunk Wall.
NBTXR3

Pigmented Villonodular Synovitis, Diffuse-type Giant Cell Tumor, Clinical Trial using nilotinib

Dana-Farber Cancer Institute - Recruiting 18 years or older.
- A Multi-Center Single Agent Phase II Study of the Efficacy of Nilotinib in Patients With Relapsed or Metastatic Pigmented Villonodular Synovitis/Tenosynovial Giant Cell Tumor/Diffuse-Type Giant Cell Tumor.
nilotinib

Tumor Pathway Activations Inhibited by Dovitinib Clinical Trial using Dovitinib (TKI258)

Novartis - Recruiting 18 years or older.
- Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module 2 - Dovitinib for Patients With Tumor Pathway Activations Inhibited by Dovitinib Including Tumors With Mutations or Translocations of FGFR, PDGFR, VEGF, cKIT, FLT3, CSFR1, Trk and RET.
Dovitinib (TKI258)

PI3K Pathway Activated Tumors Clinical Trial using BKM120

Novartis - Recruiting 18 years or older.
- Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module 1 - BKM120 for Patients With PI3K-activated Tumors.
BKM120

Recurrent or Refractory Solid Tumors, Ewing Sarcoma, Rhabdomyosar Clinical Trial using MM-398 (Irinotecan Sucrosofate Liposome Injection) plus cyclophosphamide

Merrimack Pharmaceuticals - Recruiting 12 Months to 20 years.
- Phase 1 Dose-escalating Study of MM-398 (Irinotecan Sucrosofate Liposome Injection) Plus Intravenous Cyclophosphamide in Recurrent or Refractory Pediatric Solid Tumors.
MM-398 (Irinotecan Sucrosofate Liposome Injection) plus cyclophosphamide

Sarcoma Clinical Trial using bevacizumab [Avastin]; Standard chemotherapy

Hoffmann-La Roche - Recruiting 6 Months to 18 years.
- An Open-label, Multi-center, Randomized Study of the Safety and Effect on Event-free Survival of Bevacizumab in Combination With Standard Chemotherapy in Childhood and Adolescent Patients With Metastatic Rhabdomyosarcoma and Non-rhabdomyosarcoma Soft Tissue Sarcoma.
bevacizumab [Avastin]; Standard chemotherapy

Sarcoma, Wilm's Tumor, Lymphoma, or Neuroblastoma Clinical Trial using Ipilimumab(anti-CTLA-4 antibody)

National Institutes of Health Clinical Center (CC) - Recruiting 1 year to 21 years.
- A Phase I Study of Ipilimumab (Anti-CTLA-4) in Children, Adolescents, and Young Adults With Treatment Refractory Cancer.
Ipilimumab(anti-CTLA-4 antibody)

Refractory Soft Tissue Sarcomas Clinical Trial using Cabozantinib

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- A Phase 2 Study of Cabozantinib (XL184), a Dual Inhibitor of MET and VEGFR, in Patients With Metastatic Refractory Soft Tissue Sarcoma.
Cabozantinib

Sarcoma, Alveolar Soft Part Clinical Trial using AZD2171

National Institutes of Health Clinical Center (CC) - Recruiting N/A to 16 years.
- Phase II Study of Cediranib (AZD2171) in Patients With Alveolar Soft Part Sarcoma.
AZD2171

Sarcoma, Melanoma, Epithelial Malignancies, or Pleural Malignanci Clinical Trial using Allogenic Tumor Cell Vaccine (K562)

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- Adjuvant Allogeneic Tumor Cell Vaccine With Metronomic Oral Cyclophosphamide and Celecoxib in Patients Undergoing Resection of Sarcomas, Melanomas, Germ Cell Tumors, or Epithelial Malignancies Metastatic to Lungs, Pleura, or Mediastinum.
Allogenic Tumor Cell Vaccine (K562)

Sarcoma, Soft Tissue Sarcoma, Locally Advanced Sarcoma, Unresecta Clinical Trial using Bevacizumab, Gemcitabine, docetaxel and valproic acid

University of Iowa - Recruiting 18 years or older.
- A Pilot Study Targeting Angiogenesis Using Bevacizumab Combined With Chemotherapy and Histone Deacetylase Inhibitor (Valproic Acid) in Advanced Sarcomas.
Bevacizumab, Gemcitabine, docetaxel and valproic acid

Neuroblastoma, or Sarcoma Clinical Trial using Cyclophosphamide, Topotecan, and Bevacizumab

Memorial Sloan-Kettering Cancer Center - Recruiting N/A to 21 years.
- A Phase II Trial of Cyclophosphamide, Topotecan, and Bevacizumab (CTB) in Patients With Relapsed/Refractory Ewing's Sarcoma and Neuroblastoma.
Cyclophosphamide, Topotecan, and Bevacizumab

Osteosarcoma, or Spindle Cell Sarcoma of Bone Clinical Trial using Glucarpidase; Methotrexate; Folinic Acid

University College, London - Recruiting 5 years to 50 years.
- A Randomised, Cross-over Phase II Study to Investigate the Efficacy and Safety of Glucarpidase for Routine Use After High Dose Methotrexate in Patients With Bone Sarcoma.
Glucarpidase; Methotrexate; Folinic Acid

Invasive Cancer, Sarcoma, or Hematologic Cancer Clinical Trial

M.D. Anderson Cancer Center - Recruiting N/A or older.
- Molecular Testing for the MD Anderson Cancer Center Personalized Cancer Therapy Program.

Adult Liposarcoma, Adult Synovial Sarcoma, Recurrent Adult Soft T Clinical Trial using cyclophosphamide; NY-ESO-1-specific T cells; laboratory biomarker analysis

Fred Hutchinson Cancer Research Center - Recruiting 18 years or older.
- A Phase I Study To Determine the Feasibility of Using Autologous NY-ESO-1 Specific CD8+ T Cells For the Treatment of Patients With Advanced Myxoid/ Round Cell Liposarcoma and Synovial Sarcoma..
cyclophosphamide; NY-ESO-1-specific T cells; laboratory biomarker analysis

Brain and Central Nervous System Tumors, Neuroblastoma, or Sarcom Clinical Trial using iodine I 131 monoclonal antibody 8H9

Memorial Sloan-Kettering Cancer Center - Recruiting N/A or older.
- Phase I Study Of Intrathecal Radioimmunotherapy Using I-8H9 For Central Nervous System/Leptomeningeal Neoplasms.
iodine I 131 monoclonal antibody 8H9

Sarcoma, Soft Tissue Clinical Trial using Pazopanib

Radboud University - Recruiting 18 years or older.
- Individualizing Pazopanib Therapy by exploRing the Role of Early Metabolic responsE and Drug Exposure as a preDICTor for Treatment Outcome in Patients With STS.
Pazopanib

Cervical Cancer, Endometrial Cancer, Fallopian Tube Cancer, Hered Clinical Trial using laboratory biomarker analysis; screening questionnaire administration; study of high risk factors

Northwestern University - Recruiting 18 years to 80 years.
- Northwestern Ovarian Cancer Early Detection & Prevention Program: A Specimen and Data Study.
laboratory biomarker analysis; screening questionnaire administration; study of high risk factors

Ewing's Sarcoma, or Ovarian Cancer Clinical Trial using FANG

Gradalis, Inc. - Recruiting 12 years or older.
- Phase I Trial of Bi-shRNAfurin and GMCSF Augmented Autologous Tumor Cell Vaccine for Advanced Cancer.
FANG

Adult Angiosarcoma, Recurrent Adult Soft Tissue Sarcoma, Stage II Clinical Trial using pazopanib hydrochloride; laboratory biomarker analysis; positron emission tomography; computed tomography; fludeoxyglucose F 18

Fox Chase Cancer Center - Recruiting 18 years or older.
- Phase II Study Evaluating the Role of Pazopanib in Angiosarcoma.
pazopanib hydrochloride; laboratory biomarker analysis; positron emission tomography; computed tomography; fludeoxyglucose F 18

Sarcoma, Leiomyosarcoma, Malignant Peripheral Nerve Sheath Tumor, Clinical Trial using Gemcitabine and Docetaxel in Combination with Pazopanib

Memorial Sloan-Kettering Cancer Center - Recruiting 18 years or older.
- A Phase IB/II Study of Gemcitabine and Docetaxel in Combination With Pazopanib (Gem/Doce/Pzb) for the Neoadjuvant Treatment of Soft Tissue Sarcoma (STS).
Gemcitabine and Docetaxel in Combination with Pazopanib

Stage IA Uterine Sarcoma, Stage IB Uterine Sarcoma, Stage IC Uter Clinical Trial using gemcitabine hydrochloride; docetaxel; brachytherapy; intensity-modulated radiation therapy; external beam radiation therapy; laboratory biomarker analysis

Albert Einstein College of Medicine of Yeshiva University - Recruiting 18 years or older.
- A Pilot Safety and Toxicity Trial of Adjuvant Chemotherapy With Gemcitabine and Docetaxel and Radiation Therapy for Completely Resected Uterine Leiomyosarcoma.
gemcitabine hydrochloride; docetaxel; brachytherapy; intensity-modulated radiation therapy; external beam radiation therapy; laboratory biomarker analysis

Sarcoma, Chemotherapy-induced Nausea and Vomiting, Effects of Che Clinical Trial using Fosaprepitant; Dexamethasone; 5HT3 receptor antagonist; Ifosfamide-based chemotherapy (AI); Doxorubicin; Mesna; Ifosfamide; Vincristine

M.D. Anderson Cancer Center - Recruiting 18 years to 65 years.
- Evaluation of Fosaprepitant's Effect on Drug Metabolism in Sarcoma Patients Receiving Ifosfamide-based Multi-day Chemotherapy Regimen.
Fosaprepitant; Dexamethasone; 5HT3 receptor antagonist; Ifosfamide-based chemotherapy (AI); Doxorubicin; Mesna; Ifosfamide; Vincristine

Radiation Induced Sarcoma Clinical Trial using tumor genetic predisposition to develop sarcoma assessment

Centre Georges Francois Leclerc - Recruiting 18 years or older.
- Predictive Study of Radiation Induced Sarcoma From the GSF-GETO Data Base..
tumor genetic predisposition to develop sarcoma assessment

Mucinous Adenocarcinoma of the Colon, Mucinous Adenocarcinoma of Clinical Trial using panitumumab; irinotecan hydrochloride; fluorouracil; leucovorin calcium

Ohio State University Comprehensive Cancer Center - Recruiting 18 years or older.
- A Phase II Study of Panitumumab in Combination With FOLFIRI After Progression on FOLFIRI Plus Bevacizumab in KRAS(Kirsten Rat Sarcoma) Wild-Type Metastatic Colorectal Cancer..
panitumumab; irinotecan hydrochloride; fluorouracil; leucovorin calcium

Osteosarcoma, Ewing's Sarcoma, Rhabdomyosarcoma, Synovial Sarcoma Clinical Trial using Endurance; Strengthening; Stretching; Home exercise program

St. Jude Children's Research Hospital - Recruiting 6 years to 30 years.
- A Pilot Study on the Effects of Preoperative Physical Therapy in Adolescents and Young Adults Diagnosed With a Lower Extremity Malignancy.
Endurance; Strengthening; Stretching; Home exercise program

Sarcoma Clinical Trial using microarray analysis; molecular diagnostic method; biologic sample preservation procedure

National Cancer Institute (NCI) - Recruiting 16 years or older.
- VORTEX-BIOBANK: Prospective Sample Collection for the VORTEX Randomised Radiotherapy Trial in Patients With Extremity Soft Tissue Sarcoma [VORTEX BIOBANK].
microarray analysis; molecular diagnostic method; biologic sample preservation procedure

Sarcoma Clinical Trial using dactinomycin; cyclophosphamide; vincristine sulfate; radiation therapy

National Cancer Institute (NCI) - Recruiting N/A to 17 years.
- Phase II Trial of Short VAC1.2 Therapy for Low-Risk A Group Patients With Rhabdomyosarcoma.
dactinomycin; cyclophosphamide; vincristine sulfate; radiation therapy

Chemotherapeutic Agent Toxicity, Sarcoma, or Unspecified Childhoo Clinical Trial using gene expression analysis; polymorphism analysis; management of therapy complications

National Cancer Institute (NCI) - Recruiting N/A to 20 years.
- CYP3A5 Genotype as a Potential Risk Factor for the Development of Ifosamide Nephrotoxicity in Children.
gene expression analysis; polymorphism analysis; management of therapy complications

Glioma, Neuroectodermal Tumors, Primitive, Wilms Tumor, Rhabdomyo Clinical Trial using Metronomic Cyclophosphamide; Thalidomide

Washington University School of Medicine - Recruiting 5 years to 21 years.
- Anti-Angiogenic Therapy After Autologous Stem Cell Rescue (ASCR) for Relapsed and Refractory Pediatric Solid Tumors.
Metronomic Cyclophosphamide; Thalidomide

Soft Tissue Sarcoma Clinical Trial using MRI-DCE

University of Utah - Recruiting 18 years or older.
- Pilot Study: Dynamic Contrast-enhanced Magnetic Resonance Imaging(DCE-MRI)for Assessing Tumor Vascularity and Permeability in Soft Tissue Sarcoma Treated With Preoperative Radiotherapy Followed by Surgical Resection.
MRI-DCE

Sarcoma Clinical Trial using Dacarbazine

Washington University School of Medicine - Recruiting 18 years or older.
- Determination of Tumor Response Rate by RECIST and FDG-PET Criteria to Dacarbazine in Metastatic Soft Tissue and Bone Sarcoma.
Dacarbazine

Carney Complex, Chondrosarcoma, Gastrointestinal Stromal Tumor, o Clinical Trial using linsitinib; pharmacological study; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Phase 2 Study of OSI-906 in Pediatric and Adult Wild Type Gastrointestinal Stromal Tumors.
linsitinib; pharmacological study; laboratory biomarker analysis

Clear Cell Sarcoma of the Kidney, Congenital Mesoblastic Nephroma Clinical Trial using laboratory biomarker analysis; cytology specimen collection procedure

Children's Oncology Group - Recruiting N/A to 29 years.
- Renal Tumors Classification, Biology, and Banking Study.
laboratory biomarker analysis; cytology specimen collection procedure

Soft Tissue Sarcoma Clinical Trial using Pazopanib; Doxorubicin

Hannover Medical School - Recruiting 60 years or older.
- A Randomized Phase II Trial Comparing Pazopanib With Doxorubicin as First Line Treatment in Elderly Patients With Metastatic or Advanced Soft Tissue Sarcoma.
Pazopanib; Doxorubicin

Advanced Desmoid Tumor, or Advanced Chondrosarcoma Clinical Trial using Imatinib Mesylate

Italian Sarcoma Group - Recruiting 18 years to 80 years.
- Open-label Trial of Imatinib in Patients With Desmoid Tumor and Chondrosarcoma.
Imatinib Mesylate

Soft Tissue Sarcoma Clinical Trial using proton radiation; surgery (wide local excision; limb preservation surgery)

Loma Linda University - Recruiting 18 years or older.
- A Phase II Trial of Preoperative Proton Therapy in Soft-tissue Sarcomas of the Extremities and Body Wall.
proton radiation; surgery (wide local excision; limb preservation surgery)

Sarcoma Clinical Trial using DNA analysis; gene expression analysis; protein expression analysis; reverse transcriptase-polymerase chain reaction; western blotting; immunohistochemistry staining method; laboratory biomarker analysis

University of Arizona - Recruiting N/A or older.
- LABORATORY STUDIES OF SOFT TISSUE SARCOMAS.
DNA analysis; gene expression analysis; protein expression analysis; reverse transcriptase-polymerase chain reaction; western blotting; immunohistochemistry staining method; laboratory biomarker analysis

Locally Advanced or Metastatic Soft Tissue Sarcoma Clinical Trial using NGR-hTNF; Doxorubicin

MolMed S.p.A. - Recruiting 18 years or older.
- NGR016: Randomized Phase II Study Evaluating Two Doses of NGR-hTNF Administered Either as Single Agent or in Combination With Doxorubicin in Patients With Advanced Soft Tissue Sarcoma (STS).
NGR-hTNF; Doxorubicin

Sarcoma, Neuroblastoma, Wilms Tumor, Leukemia, Lymphoma, or Brain Clinical Trial using Marqibo

Spectrum Pharmaceuticals, Inc - Recruiting 2 years to 20 years.
- Phase I Trial to Evaluate the Safety, Activity and Pharmacokinetics of Marqibo(Registered Trademark) (Vincristine Sulfate Liposomes Injection) in Children and Adolescents With Refractory Cancer.
Marqibo

Sarcoma Clinical Trial using biologic sample preservation procedure

National Cancer Institute (NCI) - Recruiting N/A or older.
- A Children's Oncology Group Protocol for Collecting and Banking Osteosarcoma Specimens.
biologic sample preservation procedure

Alveolar Soft-part Sarcoma Clinical Trial using Cediranib; Placebo

Institute of Cancer Research, United Kingdom - Recruiting 16 years or older.
- A Phase II Trial of Cediranib in the Treatment of Patients With Alveolar Soft Part Sarcoma (CASPS).
Cediranib; Placebo

Bone Metastases, Musculoskeletal Cancer, Soft Tissue Sarcoma, or Clinical Trial using acetylsalicylic acid; enoxaparin; thromboembolism prophylaxis

Ohio State University Comprehensive Cancer Center - Recruiting 18 years or older.
- Aspirin and Compression Devices for VTE Prophylaxis in Orthopaedic Oncology.
acetylsalicylic acid; enoxaparin; thromboembolism prophylaxis

Soft Tissue Sarcoma, or Lung Metastasis Clinical Trial using chest radiography; chest CT

Centre Oscar Lambret - Recruiting 18 years to 70 years.
- Phase II Study Evaluating Strategies of Lung Surveillance of Patients Operated of High Grade Soft Tissue Sarcoma: Chest Radiograph Versus Chest CT.
chest radiography; chest CT

Sarcoma Database Clinical Trial using Database

King Faisal Specialist Hospital & Research Center - Recruiting 14 years to 85 years.
- Sarcoma Database at KFSH&RC..
Database

Soft Tissue Sarcoma of Members Clinical Trial using Radiotherapy; absence of radiotherapy

Institut Claudius Regaud - Recruiting 18 years or older.
- Randomised Multicentric Phase III Study Comparing Observation Versus Post-surgery Radiotherapy After Complete Exeresis With Margins Greater Than or Equal to 1 cm in Soft Tissues Members Sarcoma..
Radiotherapy; absence of radiotherapy

Soft Tissue Sarcoma, Fibrous Histiocytoma, Liposarcoma, Leiomyosa Clinical Trial using Bevacizumab; Radiation Therapy

Massachusetts General Hospital - Recruiting 18 years or older.
- A Phase II Study of Neoadjuvant Bevacizumab and Radiation Therapy for Resectable Soft Tissue Sarcomas.
Bevacizumab; Radiation Therapy

Kaposi's Sarcoma Clinical Trial using Indinavir in association with Vinblastina +/- Bleomicina

Istituto Superiore di Sanita - Recruiting 18 years or older.
- Phase II Trial for the Treatment of Advanced Classical Kaposi's Sarcoma With the HIV Protease Inhibitor Indinavir in Combination With Chemotherapy.
Indinavir in association with Vinblastina +/- Bleomicina

Soft Tissue Sarcoma Clinical Trial using Sorafenib

Grupo Espanol de Investigacion en Sarcomas - Recruiting 18 years to 72 years.
- Phase I-II, Not-Randomized, Multicenter Clinical Trial to Evaluate Safety and Efficacy of Sorafenib (BAY-43-9006) in Combination With Ifosfamide in Soft Tissue Sarcoma..
Sorafenib

Uterine Sarcoma Clinical Trial using doxorubicin, ifosfamide, cisplatin

Gustave Roussy, Cancer Campus, Grand Paris - Recruiting 18 years to 65 years.
- Phase III Study About the Effects of the Addition of Polychemotherapy to Adjuvant Radiotherapy in the Treatment of Non-Metastatic Uterine Sarcomas.
doxorubicin, ifosfamide, cisplatin

Sarcoma of Pelvis Clinical Trial using Tasonermine (TNFa); Melphalan

Gustave Roussy, Cancer Campus, Grand Paris - Recruiting 16 years or older.
- Isolated Pelvic and Limb Perfusion With 1mg TNFa in the Treatment of Locally Advanced Sarcoma of Pelvis and Limbs' Girdle.
Tasonermine (TNFa); Melphalan